Therefore, the cytoreductive effect of dual BCL-2 and MCL1 targeting was explored across treatment naïve and chemotherapy relapsed/refractory AML samples characterized for cytogenetic abnormalities and recurrent mutations using a 54-gene targeted exome panel (Fig. 2) [24]. The gene discussed is MCL1; the disease is acute myeloid leukemia.